Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Chemo in High Grade Neuroendocrine Carcinoma
NCT03901378Phase 2Withdrawn
- Sponsor
- Ochsner Clinic Foundation
- Start
- Oct 2019
- Primary completion
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in neuroendocrine carcinoma (NEC), sponsored by Ochsner Clinic Foundation. Planned start Oct 2019; status: withdrawn.
02
Drugs
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT03901378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03901378.